{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:00Z","timestamp":1791335640052,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtocrr.2023.100584","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T02:28:02Z","timestamp":1697077682000},"page":"100584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-8945","authenticated-orcid":false,"given":"Arkadiusz Z.","family":"Dudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min X.","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Scilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirva","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Creelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Saltos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawee","family":"Tanvetyanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiappori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100584_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100584_bib3","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2021.06.017","article-title":"Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma","volume":"159","author":"Kim","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2023.100584_bib5","article-title":"Immune checkpoint inhibitor uptake in real-world patients with malignant pleural mesothelioma","volume":"2","author":"Kim","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2023.100584_bib6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100584_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","article-title":"Hypoxia promotes tumor growth in linking angiogenesis to immune escape","volume":"3","author":"Chouaib","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2008.03.012","article-title":"Myeloid-derived suppressor cell role in tumor-related inflammation","volume":"267","author":"Dolcetti","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtocrr.2023.100584_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G","article-title":"Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas","volume":"192","author":"Lewis","year":"2000","journal-title":"J\u00a0Pathol"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2023.100584_bib10","first-page":"e237","article-title":"Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin","volume":"128","author":"Yang","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jtocrr.2023.100584_bib11","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2023.100584_bib12","article-title":"Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2023.100584_bib13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.21037\/tlcr-20-1114","article-title":"Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study","volume":"10","author":"Brcic","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2023.100584_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/PAS.0b013e318243555b","article-title":"Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors","volume":"36","author":"Miettinen","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","article-title":"Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: a nonrandomized controlled trial","volume":"9","author":"Provencio","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib16","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2023.100584_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib19","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2023.100584_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of Avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib25","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2023.100584_bib26","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:38:50Z","timestamp":1762987130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2666364323001273"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100584","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100584"}}